Shrinks In Sneakers

Tag: drug use

  • ARISE Study Phase 3 Results: Understanding Xanomeline’s Setback

    ARISE Study Phase 3 Results: Understanding Xanomeline’s Setback

    What Was the ARISE Study?

    The ARISE trial was a Phase 3 clinical study evaluating Cobenfy — a combination of xanomeline (a muscarinic receptor agonist) and trospium chloride (a peripheral anticholinergic) — as an adjunctive treatment for adults with schizophrenia who continued to experience symptoms despite taking an atypical antipsychotic.

    What Is a Primary Endpoint, and Why Does It Matter?

    In clinical trials, the primary endpoint is the most important outcome researchers are trying to affect — it’s how a drug’s success or failure is officially judged.
    In ARISE, the primary endpoint measured the change in symptom severity compared to placebo using a standardized scale for schizophrenia. Meeting this endpoint would have demonstrated clear, statistically significant symptom improvement attributable to Cobenfy.

    The Outcome: No Statistically Significant Benefit

    According to topline results, Cobenfy did not show a statistically significant improvement compared to placebo when added to atypical antipsychotics. This means the observed difference could have been due to chance and did not meet the pre-set threshold for success.

    However, Cobenfy did show a numerical improvement — the group receiving the drug combination performed betterthan placebo in symptom reduction, just not to a statistically convincing degree.

    Could Anticholinergic Effects Be to Blame?

    One possible explanation for this outcome lies in the mechanism of action of both Cobenfy and many commonly used atypical antipsychotics.

    • Xanomeline is designed to activate muscarinic receptors in the brain (specifically M1 and M4), which may help regulate dopamine and reduce psychosis.
    • But many atypical antipsychotics — like olanzapine, clozapine, and quetiapine — also have anticholinergic properties, meaning they block these same receptors.

    This sets up a pharmacological tug-of-war: Cobenfy tries to stimulate muscarinic activity, while the background antipsychotic may be dampening it. This conflict could blunt the therapeutic signal, explaining why the benefit didn’t reach statistical significance.

    What This Means for the Future

    The failure to meet the primary endpoint is a setback, but not the end of the road. The numerical improvements suggest a potential signal, and with refined trial design — perhaps using background medications with lower anticholinergic load — future studies may better reveal Cobenfy’s potential.

    Additionally, this trial underscores the importance of considering mechanism compatibility in combination therapies. It’s not just about adding drugs — it’s about how they interact at the receptor level.

    Conclusion

    While the ARISE study didn’t deliver the result many hoped for, it raised critical questions that will shape future research. A deeper understanding of anticholinergic burden, drug synergy, and precision pharmacology is essential as we continue the search for more effective treatments for schizophrenia.

  • Drug Overdose: The Epidemic Stealing Parents from Their Children

    Drug Overdose: The Epidemic Stealing Parents from Their Children

    After a few years of treating patients with opioid use disorder, it becomes painfully clear how much addiction affects not just the individual but their entire family. I’m always particularly concerned when a parent with severe opioid use disorder comes in for treatment, especially if they have one or more children. We know that relapse is common, and each instance of relapse carries the risk of death due to the potency of modern opioids.

    A recent study explored the heartbreaking question of how many children have lost a parent to an overdose. The findings are staggering: from 2011 to 2021, over 320,000 children lost a parent to an overdose. This loss significantly increases the economic, social, educational, and health burdens on these children, perpetuating a cycle of harm that could affect them for the rest of their lives.

  • The Dangers of Marijuana Use While Driving

    The Dangers of Marijuana Use While Driving

    I recently had an opportunity to review an article for The Carlat Addiction Psychiatry Report on the topic of cannabis use and driving. I wanted to further evaluate the risk of cannabis use while operating a motor vehicle.

    Driving under the influence of any substance, including marijuana, poses significant risks to the driver, passengers, and others on the road. Despite its increasing legalization and acceptance for both medicinal and recreational use, marijuana remains a potent drug with effects that can impair driving abilities.

    Marijuana use and driving don’t mix:

    Impairment of Motor Skills and Reaction Time

    Slowed Reaction Time: Marijuana affects the central nervous system, leading to slower reflexes and reaction times. This delay can be crucial in driving situations that require quick decision-making, such as avoiding sudden obstacles or responding to traffic signals.

    Impaired Motor Coordination: THC, the active ingredient in marijuana, can impair fine motor skills and coordination. This makes tasks such as steering, braking, and maintaining lane position more challenging.

    Cognitive Impairments

    Altered Perception of Time and Distance: Marijuana use can distort a driver’s perception of time and distance, making it difficult to judge speed and the proximity of other vehicles or pedestrians.

    Difficulty Concentrating: Staying focused on the road becomes harder under the influence of marijuana. Distractions can increase, and the ability to track multiple moving objects is diminished.

    Increased Risk of Accidents

    • Higher Accident Rates: Studies have shown that drivers who use marijuana are more likely to be involved in motor vehicle accidents compared to sober drivers. The risk is particularly high within the first few hours after consumption.
    • Combining Substances: The dangers are amplified when marijuana is used in combination with other substances, such as alcohol. The combined effects can drastically increase the likelihood of a crash.

    Legal and Social Consequences

    DUI Charges: Driving under the influence of marijuana is illegal and can result in DUI charges, fines, license suspension, and even imprisonment.

    Insurance Implications: Being involved in an accident while under the influence can lead to increased insurance premiums or denial of coverage.

    Personal and Public Safety

    • Endangering Lives: Driving under the influence of marijuana not only endangers the driver’s life but also the lives of passengers, pedestrians, and other road users.
    • Public Health Impact: The broader societal impact includes the strain on emergency services, healthcare systems, and the economic costs associated with accidents and injuries.

    Conclusion

    The bottom line is clear: marijuana use and driving do not mix. The impairments caused by marijuana significantly increase the risk of accidents and the potential for harm. Responsible use of marijuana means understanding its effects and making informed decisions to ensure personal and public safety. If you’ve used marijuana, it’s crucial to wait until its effects have fully worn off before getting behind the wheel.